Rising Prevalence Of Esophageal Diseases Drives Growth In The Gastroesophageal Reflux Disease (GERD) Market: Strengthening the Growth Trajectory of the Gastroesophageal Reflux Disease (GERD) Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Gastroesophageal Reflux Disease (GERD) Market Through 2025?
The market for gastroesophageal reflux disease (GERD) has seen a slight expansion in recent years. It is projected to increase from $5.25 billion in 2024 to $5.35 billion in 2025, marking a compound annual growth rate (CAGR) of 2.0%. Factors contributing to the growth during the historical period include lifestyle and dietary shifts, the obesity crisis, heightened awareness of GERD treatments, the globalization of the pharmaceutical sector, and investments made towards GERD therapies.

What's the Projected Size of the Global Gastroesophageal Reflux Disease (GERD) Market by 2029?
The market for gastroesophageal reflux disease (GERD) is projected to witness steady expansion in the following years, reaching an estimated value of $5.94 billion in 2029, with a compound annual growth rate (CAGR) of 2.7%. Factors contributing to this growth during the forecast period are attributed to an aging population, elevated healthcare expenditure, the emergence of biomarker, more screenings for GERD, a rising rate of heartburn, and an increased demand for medical equipment. The forecast period is expected to see key trends such as enhancements in diagnostics and surgical procedures, the development of targeted treatments, and the introduction of telehealth services.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-gerd-global-market-report

Top Growth Drivers in the Gastroesophageal Reflux Disease (GERD) Industry: What's Accelerating the Market?
The increase in esophageal diseases is anticipated to fuel the gastroesophageal reflux disease (GERD) market's expansion. These medical conditions impact the esophagus, a muscular canal linking the mouth and stomach. Treatments for esophageal diseases aim to relieve symptoms, enhance the quality of life, and prevent further complications, thereby improving the overall health of individuals suffering from gastroesophageal reflux disease. Particularly, in January 2023, the American Cancer Society reported approximately 21,560 new instances of esophageal cancer annually in the United States, with 16,120 fatalities. Consequently, the rising prevalence of esophageal diseases is a significant driver for the growth of the gastroesophageal reflux disease (GERD) market. The gastroesophageal reflux disease (GERD) market is also anticipated to expand due to the high rate of alcohol consumption. The act of consuming beverages containing ethanol, the only drinkable alcohol type for humans, corresponds to alcohol consumption. This behavior contributes to GERD by reducing esophageal movement and pressure levels. For instance, data from July 2024, presented by the House of Commons Library, indicated that 56% of English adults consumed alcohol in the past week, in 2022. More specifically, a gender difference emerged, with 61% of men and 51% of women admitting to having drunk alcohol during that time. Therefore, the high occurrence of alcohol consumption is pushing forward the growth of the gastroesophageal reflux disease (GERD) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12917&type=smp

What Trends Will Shape the Gastroesophageal Reflux Disease (GERD) Market Through 2029 and Beyond?
Prominent companies in the gastroesophageal reflux disease (GERD) market are concentrating on launching novel GERD treatment apparatus to maintain their market standing. For example, in April 2023, the US-based medical tech firm, Laborie Medical Technologies, unveiled the alpHaONE wireless pH-capsule reflux testing diagnostic system, a newly designed tool for diagnosing GERD. The system can monitor data for up to 96 hours, boasts a compact build with bigger buttons, and features a foolproof capsule delivery system. The system also includes a software application with a digital instruction guide and customizable symptom buttons for an enhanced user interface.

What Are the Main Segments in the Gastroesophageal Reflux Disease (GERD) Market?
The gastroesophageal reflux disease (GERD) market covered in this report is segmented -

1) By Drug Type: Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless Fundoplication (TIF)
2) By Procedure: Invasive, Minimally Invasive
3) By End-Users: Hospital, Homecare, Specialty Clinics

Subsegments:
1) By Antacids: Calcium Carbonate, Magnesium Hydroxide, Aluminum Hydroxide
2) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole
3) By H2 Receptor Blockers: Ranitidine, Famotidine, Nizatidine, Cimetidine
4) By Prokinetic Agents: Metoclopramide, Domperidone
5) By Dopamine Receptor Antagonists: Prochlorperazine, Droperidol
6) By EndoCinch: Endoscopic Suturing Systems
7) By Stretta: Radiofrequency Ablation Systems
8) By EsophyX: Transoral Fundoplication Systems
9) By Transoral Incisionless Fundoplication (TIF): TIF Devices And Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12917&type=smp

Which Top Companies are Driving Growth in the Gastroesophageal Reflux Disease (GERD) Market?
Major companies operating in the gastroesophageal reflux disease (GERD) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.

Which Regions Will Dominate the Gastroesophageal Reflux Disease (GERD) Market Through 2029?
North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12917

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.